<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456885</url>
  </required_header>
  <id_info>
    <org_study_id>2006P000361</org_study_id>
    <secondary_id>BFA912</secondary_id>
    <nct_id>NCT00456885</nct_id>
  </id_info>
  <brief_title>The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women</brief_title>
  <official_title>The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the effect of exenatide, a drug which has been approved for the
      treatment of type 2 diabetes, on body weight, appetite and energy expenditure among
      moderately obese women without diabetes.

      The study is 35 weeks long and includes 19 outpatient visits. Participants will receive
      exenatide for 16 weeks and placebo for 16 weeks with a 3 week rest period in between. Neither
      participants nor investigators will know whether exenatide or placebo is being administered.
      Participants will be started randomly on either exenatide or placebo.

      Our hypothesis is that treatment with exenatide will curb appetite and lead to weight loss
      and may lead to changes in energy expenditure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the effect of exenatide on body weight, energy expenditure, satiety,
      sleep, and metabolic parameters in healthy, moderately obese women (BMI 28-35 kg/m2). We will
      look at 2 populations of women, one with normal glucose metabolism and one with impaired
      glucose homeostasis (IGH)--either impaired fasting glucose (IFG, fasting glucose 101-125
      mg/dL) or impaired glucose tolerance (IGT, glucose 140-199 mg/dL 2h after a 75g oral glucose
      load). This is a randomized, double blind, crossover study with two 16-week treatment periods
      separated by a 3-week washout period. There are 19 study visits over 35 weeks.

      The goals of this study are 1) to examine the effect of exenatide on body weight and
      dysglycemia in populations in which this medication has not been studied, namely obese women
      with and without IGH and 2) to investigate possible mechanisms of weight loss through
      measurements of energy expenditure, hunger, satiety, nausea, and sleep.

      The primary outcome of this study is weight loss. We will calculate absolute and relative
      change in body weight from baseline to week 16 (the first treatment period) and from week 19
      to week 35 (the second treatment period). Body weight will be measured at every study visit
      which will also allow us to assess the absolute and relative change from baseline throughout
      the entire study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>16 weeks after the beginning of each treatment</time_frame>
    <description>Change in weight at the end of each treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>16 weeks after the beginning of each treatment</time_frame>
    <description>Blood pressure was measured using a Dynamap automated monitoring device. The change is reported as the blood pressure measured at the beginning of the treatment group and after 16 weeks. We are reporting the change in the systolic blood presssure recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Composition</measure>
    <time_frame>16 weeks after the beginning of each treatment</time_frame>
    <description>Per cent body body fat was assessed using bio-electrical impedance with a BIA; RJL System Quantum II Bioelectrical Body Composition Analyzer. The data is reported as per cent body fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Leptin</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>16 weeks after the beginning of each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>16 weeks after the beginning of each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Two Hour Glucose</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA Score</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REE</measure>
    <time_frame>16 weeks from the start of each treatment period.</time_frame>
    <description>Resting Energy Expenditure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Obesity</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Exenatide First</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Started on Exenatide, 3 week washout, start placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Started on placebo, 3 week washout, start exenatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks</description>
    <arm_group_label>Exenatide First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Twice daily injection of placebo</description>
    <arm_group_label>Exenatide First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged 25-60

          2. BMI 28-35 kg/m2

          3. No known diagnosis of diabetes

          4. No known diagnosis of coronary heart disease

          5. Self-described sedentary lifestyle with minimal regular cardiovascular exercise (no
             more than 1 hour per week)

          6. Stable weight (variation &lt; 3 kg within 6 months of screening visit)

          7. Ability to give informed consent

          8. Ability to follow verbal and written instructions

          9. Use of medically approved form of contraception (monophasic oral contraception, intra
             uterine device, surgical sterilization or 2 combined barrier methods)

         10. Nonsmoker (tobacco, marijuana)

         11. Outpatient visits every 2 weeks throughout the study period are required. While most
             of these visits are short (15 minutes)ability to commute to the performance site in
             Boston, on a regular basis, is necessary.

        Exclusion Criteria:

          1. Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes
             Association criteria

          2. Coronary heart disease (history of myocardial infarction or unstable angina pectoris)

          3. Uncontrolled hypertension hypertension (BP &gt; 150/90 mmHg on or off antihypertensive
             medication)

          4. Uncontrolled dyslipidemia (LDL &gt; 200 or TG &gt; 400 on or off lipid lowering medication)

          5. Tobacco, marijuana or intravenous drug use

          6. Shift workers (night shift or alternating day/night shifts)

          7. Recent weight loss (&gt; 3 kg within 4 months of the screening visit)

          8. Gastroparesis

          9. Inflammatory bowel disease

         10. Malignancy treated with chemotherapy within the past 3 years

         11. History of pancreatitis

         12. Depression requiring hospitalization or diagnosis of psychosis

         13. Renal insufficiency (creatinine clearance &lt; 50 ml/min)

         14. Transaminases &gt; 2x above the normal range

         15. Pregnancy within 6 months of the screening visit

         16. Breastfeeding

         17. Failure to use medically approved contraceptive methods

         18. History of an eating disorder (anorexia, bulimia or laxative abuse)

         19. History of surgery for the treatment of obesity (gastric banding, gastric bypass,
             gastric stapling)

         20. New diagnosis of hypo or hyperthyroidism within 1 year of screening visit

         21. Previous participation in a clinical study with exenatide

         22. Presence or history of allergic reaction to multiple drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleftheria Maratos-Flier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, Mullington J, Maratos-Flier E. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012 Jan;35(1):4-11. doi: 10.2337/dc11-0931. Epub 2011 Oct 31.</citation>
    <PMID>22040840</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <results_first_submitted>March 30, 2017</results_first_submitted>
  <results_first_submitted_qc>August 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2017</results_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Eleftheria Maratos-Flier</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>double blind</keyword>
  <keyword>placebo controlled</keyword>
  <keyword>weight loss</keyword>
  <keyword>appetite</keyword>
  <keyword>energy expenditure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Flyers, Craig's list, posters used for recruitment.Recruitment occurred between 2007 and 2010. After telephone screen subjects were evaluated at the BIDMC clinical research center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide First, Then Placebo</title>
          <description>Started on exenatide, 3 week washout, started on placebo.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Exenatide</title>
          <description>Started on placebo, three week washout, started on exenatide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment Period, 16 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout, 3 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Treatment Period, 16 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/meter^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA IR</title>
          <description>This is the ratio of fasting glucose to fasting insulin. It has no definable upper limit. We are showing scores in our study participants.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist</title>
          <description>centimeters</description>
          <units>centrimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Fat</title>
          <description>Measured using bio-electrical impedance</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic BP</title>
          <units>mm of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic BP</title>
          <units>mm of Mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Insulin</title>
          <units>mU per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Two Hour Glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adiponectin</title>
          <units>micrograms/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leptin</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Resting Energy Expenditure</title>
          <description>Using indirect calorimetry</description>
          <units>Kilocalories</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1439" spread="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight</title>
        <description>Change in weight at the end of each treatment period.</description>
        <time_frame>16 weeks after the beginning of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>Change in weight at the end of each treatment period.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="0.66"/>
                    <measurement group_id="O2" value="0.43" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Mass Index</title>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" lower_limit="-1.44" upper_limit="-0.41"/>
                    <measurement group_id="O2" value="0.18" lower_limit="-0.31" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" lower_limit="-3.3" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="0.94" lower_limit="-0.59" upper_limit="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Blood pressure was measured using a Dynamap automated monitoring device. The change is reported as the blood pressure measured at the beginning of the treatment group and after 16 weeks. We are reporting the change in the systolic blood presssure recorded.</description>
        <time_frame>16 weeks after the beginning of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Blood pressure was measured using a Dynamap automated monitoring device. The change is reported as the blood pressure measured at the beginning of the treatment group and after 16 weeks. We are reporting the change in the systolic blood presssure recorded.</description>
          <units>mm of mercury</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-6.6" upper_limit="1.6"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-5.2" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Body Composition</title>
        <description>Per cent body body fat was assessed using bio-electrical impedance with a BIA; RJL System Quantum II Bioelectrical Body Composition Analyzer. The data is reported as per cent body fat.</description>
        <time_frame>16 weeks after the beginning of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Body Composition</title>
          <description>Per cent body body fat was assessed using bio-electrical impedance with a BIA; RJL System Quantum II Bioelectrical Body Composition Analyzer. The data is reported as per cent body fat.</description>
          <units>per cent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.5" upper_limit="0.7"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-1.8" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Leptin</title>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Leptin</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-7.4" upper_limit="0.05"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-3.8" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <time_frame>16 weeks after the beginning of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mm of mercury</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-3.6" upper_limit="1.1"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-2.6" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin</title>
        <time_frame>16 weeks after the beginning of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin</title>
          <units>microgram per ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-0.3" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-0.5" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin</title>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin</title>
          <units>microunits per liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-0.6" upper_limit="2.8"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose</title>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-3.6" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.1" lower_limit="-0.7" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Two Hour Glucose</title>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Two Hour Glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-21" upper_limit="1.2"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-11" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HOMA Score</title>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>HOMA Score</title>
          <units>Ratio fasting glucose to insulin</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.3" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.3" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>REE</title>
        <description>Resting Energy Expenditure</description>
        <time_frame>16 weeks from the start of each treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>All participants that received exenatide.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants that received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>REE</title>
          <description>Resting Energy Expenditure</description>
          <units>Kilocalories</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" lower_limit="-60.6" upper_limit="33.2"/>
                    <measurement group_id="O2" value="6.5" lower_limit="-38.0" upper_limit="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>37 weeks</time_frame>
      <desc>Adverse effects were monitored as all participant adverse events and were not monitored by intervention or sequence.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <description>Bloating</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Irritation at injection site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jody Dushay</name_or_title>
      <organization>BIDMC</organization>
      <phone>6177353343 ext 617</phone>
      <email>jdushay@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

